Researchers from the National Scientific and Technical Research Council of Argentina have achieved a breakthrough against glioblastoma, the most common malignant brain tumour in adults, characterised by high invasiveness and resistance to chemotherapy and radiotherapy, with a median survival of 9 months and a five-year rate of 7 per cent.
The study, according to BRICSLat, a partner of TV BRICS, focuses on the Foxp3 protein, present in glioblastoma cells, which promotes cell migration and endothelial cell proliferation. Blocking Foxp3 using an experimental peptide called P60 improved the efficacy of chemotherapy and radiotherapy, reduced tumour cell viability and migration, and inhibited endothelial proliferation.
In animal models, the administration of P60 via an adenoviral vector eradicated the tumour and prolonged survival in one-third of treated mice, without neurotoxic effects. According to Marianela Candolfi, the study’s leader, Foxp3 represents a promising therapeutic target, although further research is needed before advancing to clinical trials in patients.
Efforts to combat cancer are also progressing in BRICS countries with innovative and multidisciplinary approaches.
According to Metrópoles, a TV BRICS partner, in Brazil, chemical researcher Livia Eberlin developed a pen capable of detecting tumour cells in real time using a high-resolution mass spectrometer connected to artificial intelligence. The device analyses the molecular signatures of tissues in just 90 seconds and is being tested in clinical trials with lung and thyroid cancer patients.
The technology has also shown promising results in breast, brain, ovarian, and prostate tumours and seeks to adapt to local needs for wider application in the country.
In India, scientists at the National Institute of Technology Rourkela discovered that piperlongumine, a natural compound present in long pepper, selectively eliminates colon cancer cells without affecting healthy ones, offering a safer alternative to conventional chemotherapy, according to IANS, a partner of TV BRICS.
Meanwhile, in China, researchers from Zhejiang University and the First Affiliated Hospital of the China Medical University reprogrammed mast cells (immune cells) to attack “cold” tumours that are difficult to treat, using IgE antibodies and oncolytic viruses to activate the immune system and suppress tumour growth, including melanoma, breast cancer, and lung metastases. This was reported by Xinhua News Agency, a TV BRICS partner.
African Times published this article in partnership with International Media Network TV BRICS
